Digitisation | November 03, 2023
Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
RHTC will address a long-standing healthcare access issue for all the local population
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Subscribe To Our Newsletter & Stay Updated
